Post-treatment Surveillance in HPV+ Oropharyngeal SCC
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04965792 |
Recruitment Status :
Active, not recruiting
First Posted : July 16, 2021
Last Update Posted : July 13, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HPV Oropharyngeal Squamous Cell Carcinoma | Other: Screening |
This research study involves blood tests to detect HPV DNA at regular time points after treatment for HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC). Participants may undergo scans based on the results of the blood tests. Study participants will also be asked to complete quality of life questionnaires periodically.
Participation in this study may last for up to 5 years. It is expected that about 150 people will take part in this research study.
Study Type : | Observational |
Estimated Enrollment : | 150 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Circulating HPV DNA for Post-treatment Surveillance in HPV-positive Oropharyngeal Squamous Cell Carcinoma |
Actual Study Start Date : | November 19, 2020 |
Estimated Primary Completion Date : | November 2026 |
Estimated Study Completion Date : | November 2027 |
Group/Cohort | Intervention/treatment |
---|---|
HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients
Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.
|
Other: Screening
Blood test |
- Recurrent disease Rate [ Time Frame: Up to 5 years ]The proportion of patients with recurrence first detected by ctHPV DNA will be calculated as a percentage and 95% confidence intervals (CI) established using binomial exact calculation.
- Recurrence Detection Predictive Properties [ Time Frame: Time from first positive ctHPV DNA test to diagnosis of recurrence, assessed up to 5 years ]Estimate positive and negative predictive value, sensitivity and specificity of ctHPV DNA for subsequent diagnosis of recurrent HPV-OPC
- Time to diagnosis of recurrence [ Time Frame: Time from first positive ctHPV DNA test to confirmed diagnosis of recurrence, assessed up to 5 years ]The median (IQR) number of months between the first positive ctHPV DNA test to definitive diagnosis of recurrence will be calculated.
- Progression-free survival (PFS) [ Time Frame: Time from registration to the earlier of progression or death due to any cause, assessed up to 5 years ]Calculated using Kaplan Meier method
- Overall survival (OS) [ Time Frame: Time from registration to death due to any cause, or censored at date last known alive, assessed up to 5 years ]Calculated using Kaplan Meier method
- Quality of Life (QOL) [ Time Frame: Pre-study, at 3 and 6 months, then at every other visit for the duration of the study up to 5 years ]QOL will be evaluated using the by Fear of Recurrence Questionnaire-Short Form (score range 6-40; lower score is lower fear of recurrence) and EQ-5D-5L questionnaire (5 questions with score range 1-5 where higher score is worse; and one question with score range 0-100 where higher is better).
- Cost Comparison [ Time Frame: Up to 5 years ]Projected cost of ctHPV DNA-based compared with standard surveillance
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Participants must have histologically or cytologically confirmed incident or recurrent squamous cell carcinoma of the tonsil or base of tongue (oropharynx) - includes biopsy of any lymph node with clinical evidence of an oropharynx tumor (unknown primary carcinoma in an involved cervical neck lymph node is permitted if high-risk HPV testing is positive on the involved node)
- HPV-associated tumor as defined by one or more : positive p16 immunohistochemistry (>70%) OR in situ hybridization OR PCR-based methods
- Age 18 years or older
- Will undergo oropharyngeal cancer treatment with curative intent
- Ability to understand and the willingness to sign a written informed consent document.
- Baseline positive or detectable ctHPV DNA result in plasma OR detectable corresponding HPV DNA in tumor tissue prior to treatment
Exclusion Criteria:
- Distant metastatic disease (M1, AJCC 8th edition)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04965792
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 |
Principal Investigator: | Eleni M Rettig, MD | Brigham and Women's Hospital |
Responsible Party: | Eleni Marie Rettig, MD, Principal Investigator, Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT04965792 |
Other Study ID Numbers: |
20-340 |
First Posted: | July 16, 2021 Key Record Dates |
Last Update Posted: | July 13, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
Time Frame: | Data can be shared no earlier than 1 year following the date of publication |
Access Criteria: | Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu Contact the Partners Innovations team at http://www.partners.org/innovation |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
HPV Oropharyngeal Squamous Cell Carcinoma HPV + Oropharyngeal Squamous Cell Carcinoma |
Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Neoplasms, Squamous Cell Head and Neck Neoplasms Neoplasms by Site |